Lilly scores with new RA med; Bayer trounces FTC's marketing lawsuit; NICE greenlights Zydelig in CLL, rejects Otezla for psoriasis;

> Eli Lilly & Co. ($LLY) and Incyte ($INCY) said their experimental rheumatoid arthritis drug baricitinib beat a standard therapy, methotrexate, at quashing symptoms of the disorder. Report

> Bayer beat back allegations from the Federal Trade Commission, which had sued the drugmaker over marketing claims about a dietary supplement, Phillips' Colon Health. Report

> England's cost-effectiveness watchdogs gave their final blessing to Gilead Sciences' ($GILD) leukemia drug Zydelig, but nixed Celgene's ($CELG) anti-inflammatory drug Otezla for psoriasis. Report | Report

> AstraZeneca's ($AZN) new dose of Brilinta is available in U.S. pharmacies, the company said. Release

> Merck KGaA's consumer health business is looking to Latin America for growth. Release

And Finally... Novartis ($NVS) used fitness wearables in a virtual triathlon challenge for employees. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.